NCT05886257

Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

Candonilimab Plus Bevacizumab as Second-line Treatment for Patients With Advanced Hepatocellular Carcinoma Who Progressed on Atezolizumab Plus Bevacizumab: a Single Arm, Phase 2 Trial

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Shi Ming · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Detailed description

Atezolizumab plus bevacizumab is the first-line treatent for patients with advanced hepatocellular carcinoma. However, the second-line treatment is absent for patients who progressed on atezolizumab plus bevacizumab. Candonilimab is a humanized bisspecific monoclonal antibody against PD-1/CTLA-4 IgG1. Candonilimab plus lenvatinib showed strong anti-tumor effect, with objective response of 44%. This single-arm, prospective, phase 2 trial is to explore the efficacy and safety of candonilimab plus bevacizumab for patients with advanced hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
DRUG	Candonilimab	10mg/kg, iv.drip, every 3 week
DRUG	Bevacizumab	15mg/kg, iv.drip, every 3 week

Timeline

• Start date: 2022-12-07
• Primary completion: 2023-03-31
• Completion: 2023-03-31
• First posted: 2023-06-02
• Last updated: 2023-06-02

Locations

1 site across 1 country: China